[ad_1]
Photograph of David Paul Morris / Bloomberg
Text size
Gilead Sciences
The shares (ticker: GILD) rose after trading hours on Thursday after biotechnology reported a first-quarter profit slightly higher than estimates.
The story back. Gilead started the year on the wrong foot, after its fourth quarter earnings exceeded expectations. The stock was then confronted with questions about the sales of some of its best-known franchises in a context of increased competition. The test data was random this year as well. Gilead's NASH drug, which had already sparked investor optimism, did not deliver the desired results, while its treatment with rheumatoid arthritis, rheumatoid arthritis, has withstood the tests better.
While some worry about the specter of drug price regulation or health care reform as the election cycle heats up, other analysts have praised the title and have stated that Gilead's earnings were still defensible. The stock is up 4.4% since the beginning of the year, but remains down 0.2% in the last 12 months.
What's up. After the bell on Thursday, Gilead said it had earned $ 1.76 per share on revenue of $ 5.28 billion, while analysts were seeking EPS of $ 1.61 per share on revenue of $ 5.29 billion of dollars. For the full year, Gilead said it expects earnings per share of between $ 1.40 and $ 1.50, although this includes non-recurring items and expenses, hence the gap between this and the consensus estimate of $ 6.64 per share. The company's revenue is $ 21.3 billion to $ 21.8 billion, compared to $ 21.9 billion for analysts.
Look to the front. Even relatively optimistic analysts did not have high expectations for the quarter. The fact that Gilead was significantly above his estimates is therefore good news – and an interesting change from his poor February report.
We will have more details on the teleconference, which starts at 16:30.
Gilead shares rose 1.2% to $ 66.09 in recent transactions.
Write to Teresa Rivas at [email protected]
[ad_2]
Source link